scholarly article | Q13442814 |
P356 | DOI | 10.1002/IJC.27888 |
P698 | PubMed publication ID | 23034738 |
P50 | author | Yung-Jue Bang | Q16180903 |
Do-Youn Oh | Q87569618 | ||
Tae-You Kim | Q87569625 | ||
Kyung Hun Lee | Q87845591 | ||
Seung-Yong Jeong | Q89340434 | ||
Sae-Won Han | Q91404079 | ||
Nam-Yun Cho | Q104742774 | ||
Jae-Gahb Park | Q117206993 | ||
Gyeong Hoon Kang | Q56613348 | ||
Seock-Ah Im | Q58821370 | ||
P2093 | author name string | Kyu Joo Park | |
Tae-Yong Kim | |||
Hyun-Jung Lee | |||
Jeong Mo Bae | |||
P2860 | cites work | Global cancer statistics | Q22241238 |
Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer | Q24614511 | ||
Molecular origins of cancer: Molecular basis of colorectal cancer | Q24617331 | ||
Microsatellite instability in colorectal cancer | Q24627393 | ||
Neurogenin promotes neurogenesis and inhibits glial differentiation by independent mechanisms | Q28203690 | ||
CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer | Q29614277 | ||
Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials | Q31014850 | ||
Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample | Q33383866 | ||
Microsatellite instability as a marker of prognosis and response to therapy: a meta-analysis of colorectal cancer survival data | Q33631924 | ||
The CpG island methylator phenotype may confer a survival benefit in patients with stage II or III colorectal carcinomas receiving fluoropyrimidine-based adjuvant chemotherapy | Q33986683 | ||
Prognostic significance of CDKN2A (p16) promoter methylation and loss of expression in 902 colorectal cancers: Cohort study and literature review. | Q34217637 | ||
The chromosomal instability pathway in colon cancer | Q34570062 | ||
Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial | Q34607843 | ||
5-Fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer. | Q34777582 | ||
DNA methylation predicts recurrence from resected stage III proximal colon cancer | Q35051119 | ||
Precision and performance characteristics of bisulfite conversion and real-time PCR (MethyLight) for quantitative DNA methylation analysis | Q35790157 | ||
Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample | Q35855515 | ||
Evidence for BRAF mutation and variable levels of microsatellite instability in a syndrome of familial colorectal cancer | Q36070164 | ||
Molecular classification and correlates in colorectal cancer | Q36329300 | ||
Association between chromosomal instability and prognosis in colorectal cancer: a meta-analysis | Q37118308 | ||
Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. | Q37157691 | ||
CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer | Q37185561 | ||
Nationwide cancer incidence in Korea, 2003-2005. | Q37376891 | ||
Worldwide variations in colorectal cancer | Q37629430 | ||
The role of the CpG island methylator phenotype in colorectal cancer prognosis depends on microsatellite instability screening status | Q38417609 | ||
Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer | Q38449001 | ||
Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy | Q43208381 | ||
Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin | Q43260542 | ||
Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases | Q43735744 | ||
Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer | Q44217665 | ||
Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. | Q44919656 | ||
Prognostic implications of CpG island hypermethylator phenotype in colorectal cancers. | Q51603737 | ||
P433 | issue | 9 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | colorectal cancer | Q188874 |
microsatellite | Q265193 | ||
P304 | page(s) | 2209-2216 | |
P577 | publication date | 2012-10-29 | |
P1433 | published in | International Journal of Cancer | Q332492 |
P1476 | title | Methylation and microsatellite status and recurrence following adjuvant FOLFOX in colorectal cancer | |
P478 | volume | 132 |
Q37100708 | Adverse prognostic impact of the CpG island methylator phenotype in metastatic colorectal cancer |
Q41390136 | Analysis of the expression level and methylation of tumor protein p53, phosphatase and tensin homolog and mutS homolog 2 in N-methyl-N-nitrosourea-induced thymic lymphoma in C57BL/6 mice |
Q40198390 | Association between mutations of critical pathway genes and survival outcomes according to the tumor location in colorectal cancer. |
Q54297781 | Combined methylation of p16 and hMLH1 (CMETH2) discriminates a subpopulation with better prognosis in colorectal cancer patients with microsatellite instability tumors. |
Q55071626 | Combined microsatellite instability and BRAF gene status as biomarkers for adjuvant chemotherapy in stage III colorectal cancer. |
Q28066004 | CpG Island Methylator Phenotype-High Colorectal Cancers and Their Prognostic Implications and Relationships with the Serrated Neoplasia Pathway |
Q34177058 | CpG island methylator phenotype and prognosis of colorectal cancer in Northeast China. |
Q50607666 | CpG island methylator phenotype is associated with the efficacy of sequential oxaliplatin- and irinotecan-based chemotherapy and EGFR-related gene mutation in Japanese patients with metastatic colorectal cancer. |
Q26768471 | Different definitions of CpG island methylator phenotype and outcomes of colorectal cancer: a systematic review |
Q35831602 | Different prognostic effect of CpG island methylation according to sex in colorectal cancer patients treated with adjuvant FOLFOX. |
Q92479179 | Epigenetic Biomarkers in Colorectal Cancer Patients Receiving Adjuvant or Neoadjuvant Therapy: A Systematic Review of Epidemiological Studies |
Q36893961 | Evaluation of CpG Island Methylator Phenotype as a Biomarker in Colorectal Cancer Treated With Adjuvant Oxaliplatin |
Q43572389 | Expression status of wild-type HSP110 correlates with HSP110 T17 deletion size and patient prognosis in microsatellite-unstable colorectal cancer |
Q26851060 | FOLFOX/FOLFIRI pharmacogenetics: the call for a personalized approach in colorectal cancer therapy |
Q37695253 | Future directions for the early detection of colorectal cancer recurrence |
Q48259649 | Genetic variants as potential predictive biomarkers in advanced colorectal cancer patients treated with oxaliplatin-based chemotherapy |
Q37708015 | Molecular and prognostic heterogeneity of microsatellite-unstable colorectal cancer. |
Q35761956 | Molecular markers predictive of chemotherapy response in colorectal cancer |
Q26785725 | Molecular phenotypes of colorectal cancer and potential clinical applications |
Q47193672 | Optimizing prognosis-related key miRNA-target interactions responsible for cancer metastasis |
Q64930417 | P16 Methylation Leads to Paclitaxel Resistance of Advanced Non-Small Cell Lung Cancer. |
Q56089175 | Pathway analysis of genetic variants in folate-mediated one-carbon metabolism-related genes and survival in a prospectively followed cohort of colorectal cancer patients |
Q36896188 | Prognostic implication of mucinous histology in colorectal cancer patients treated with adjuvant FOLFOX chemotherapy |
Q34553646 | Prognostic value of CpG island methylator phenotype among colorectal cancer patients: a systematic review and meta-analysis. |
Q43462756 | Prognostic value of p16 promoter hypermethylation in colorectal cancer: a meta-analysis |
Q64070757 | Roles of Methylated DNA Biomarkers in Patients with Colorectal Cancer |
Q26751035 | Serrated colorectal cancer: Molecular classification, prognosis, and response to chemotherapy |
Q57801319 | The hypermethylation of p16 gene exon 1 and exon 2: potential biomarkers for colorectal cancer and are associated with cancer pathological staging |
Q38730744 | The therapeutic potential of targeting the BRAF mutation in patients with colorectal cancer |
Q39194676 | p16 Methylation is associated with chemosensitivity to fluorouracil in patients with advanced gastric cancer |